Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder

March 1, 2023

https://www.globenewswire.com/news-release/2023/02/28/2617744/0/en/Landos-Biopharma-Announces-Transfer-of-LANCL-Portfolio-including-Omilancor-LABP-104-and-LABP-111-to-Landos-Founder.html

Transaction Solidifies Company’s Near-Term Strategic Focus on Advancing Clinical Development of NX-13

Company Remains On-Track to Initiate the NX-13 Phase 2 Proof-of-Concept Trial in Ulcerative Colitis in the Second Quarter of 2023

Read more at globenewswire.com

Related news for (LABP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.